SPSujin Park

Sujin Park

*This is an algorithmically generated author record based on publicly available information.

Sujin Park has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tm4sf19 inhibition alleviates imiquimod-induced psoriatic dermatitis by regulating inflammatory signaling pathways and keratinocyte proliferation in mice

    by Min Gi Kang, Sujin Park, Eunji Hong, Min-Jung Lee, Da Seul Jung, Jin Sun Heo, Haein An, Min Woo Kim, Naim Park, Hyeyeon Park, et al.

    Psoriasis is a chronic inflammatory disease characterized by keratinocyte hyperproliferation, immune cell infiltration, and persistent inflammatory signaling. Although Tm4sf19 has been implicated in inflammatory processes, its contribution to psoriasis pathogenesis remains unclear. We investigate the role of Tm4sf19 in psoriatic inflammation was examined using an imiquimod-induced psoriasis mouse model and HaCaT keratinocytes, in which Tm4sf19 expression was deleted genetically or suppressed pharmacologically with the competitive inhibitor, LEL-Fc. Gene expression, protein expression, and tissue changes were assessed by qPCR, western blotting and histological scoring, respectively. Tm4sf19 expression was significantly elevated in psoriatic lesion. Tm4sf19 knockout or inhibition using LEL-Fc suppressed psoriatic symptoms, macrophage-mediated inflammation and inflammatory cytokine expression. Tm4sf19 inhibition also suppressed the activation of STAT3, EGFR, ERK and KRT17 signaling pathways in keratinocytes. Furthermore, LEL-Fc treatment effectively inhibited LPS-induced cell cycle progression and promoted apoptosis in keratinocyte both in vivo and in vitro. These findings suggest that Tm4sf19 regulates psoriatic inflammation and keratinocyte proliferation through major signaling pathways. Therefore, inhibiting Tm4sf19 may have therapeutic potential for the treatment of psoriasis.

  • Open Access

    N-linked glycosylation is essential for anti-tumor activities of KIAA1324 in gastric cancer

    by Rebecca Yun, Eunji Hong, Junil Kim, Bora Park, Staci Jakyong Kim, Bona Lee, Yong Sang Song, Seong-Jin Kim, Sujin Park, Jin Muk Kang

    KIAA1324 is a transmembrane protein largely reported as a tumor suppressor and favorable prognosis marker in various cancers, including gastric cancer. In this study, we report the role of N-linked glycosylation in KIAA1324 as a functional post-translational modification (PTM). Loss of N-linked glycosylation eliminated the potential of KIAA1324 to suppress cancer cell proliferation and migration. Furthermore, we demonstrated that KIAA1324 undergoes fucosylation, a modification of the N-glycan mediated by fucosyltransferase, and inhibition of fucosylation also significantly suppressed KIAA1324-induced cell growth inhibition and apoptosis of gastric cancer cells. In addition, KIAA1324-mediated apoptosis and tumor regression were inhibited by the loss of N-linked glycosylation. RNA sequencing (RNAseq) analysis revealed that genes most relevant to the apoptosis and cell cycle arrest pathways were modulated by KIAA1324 with the N-linked glycosylation, and Gene Regulatory Network (GRN) analysis suggested novel targets of KIAA1324 for anti-tumor effects in the transcription level. The N-linked glycosylation blockade decreased protein stability through rapid proteasomal degradation. The non-glycosylated mutant also showed altered localization and lost apoptotic activity that inhibits the interaction between GRP78 and caspase 7. These data demonstrate that N-linked glycosylation of KIAA1324 is essential for the suppressive role of KIAA1324 protein in gastric cancer progression and indicates that KIAA1324 may have anti-tumor effects by targeting cancer-related genes with N-linked glycosylation. In conclusion, our study suggests the PTM of KIAA1324 including N-linked glycosylation and fucosylation is a necessary factor to consider for cancer prognosis and therapy improvement.